by April Breyer Menon | Feb 9, 2023
Download PDF Download...
by April Breyer Menon | Feb 3, 2023
On January 31, 2023, Amjevita™ (adalimumab-atto) entered the U.S. market as the first biosimilar of Humira® (adalimumab), after receiving approval in September 2016. Amjevita will be available in a low-concentration, citrate-free formulation (40 mg/0.8mL and...
by April Breyer Menon | Jan 12, 2023
Download PDF Download...
by April Breyer Menon | Dec 14, 2022
Download PDF Download...
by April Breyer Menon | Nov 30, 2022
On November 17, 2022, Senator Mike Lee (R-UT) introduced the “Biosimilar Red Tape Elimination Act” to increase biosimilar competition and reduce patient costs by prohibiting the FDA from requiring switching studies to approve a biosimilar as interchangeable. Unlike...